Time will tell: Circadian clock dysregulation in triple negative breast cancer.

Time will tell: Circadian clock dysregulation in triple negative breast cancer. Front Biosci (Schol Ed). 2019 Mar 01;11:178-192 Authors: Rida P, Syed MI, Aneja R Abstract Growing evidence now links circadian disruption (CD) to increased risk of developing multiple types of cancer, including breast cancer (BC). In the US, African-American (AA) BC patients have a higher mortality rate than European-Americans (EAs) with BC, and a prime suspect in this racially disparate burden has been the greater incidence of an aggressive and highly heterogeneous BC subtype called triple-negative BC (TNBC), among AAs. AAs are also more prone to CD as larger proportions of AAs engage in night shift work than EAs, and the chronotype of AAs makes it harder for them to adapt to CD than EAs. Although clock gene dysregulation has been shown to perturb transactivation of key cell cycle and apoptosis regulators, little is known about how clock gene mis-expression affects TNBC outcomes. This review examines the prognostic value of clock genes in TNBC, and evaluates patterns of clock gene dysregulation in the individual TNBC molecular subtypes. Better understanding of how CD contributes to TNBC biology may illuminate new paths to improving disease outcomes and reducing BC-related racial disparities. PMID: 30844743 [PubMed - in process]
Source: Frontiers in Bioscience - Scholar - Category: Biomedical Science Tags: Front Biosci (Schol Ed) Source Type: research